Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if administration of rituximab blocks the
development of donor specific antibodies (DSA) in transplant recipients who have developed
renal dysfunction and DSA after renal transplant. It is hoped that by blocking DSA production
renal function will stabilize or improve.